Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.
View Top Employees from Oragenics, IncWebsite | http://www.oragenics.com |
Ticker | OGEN |
Revenue | $87000 |
Employees | 18 (13 on RocketReach) |
Founded | 1996 |
Address | 4902 Eisenhower Blvd Suite 125, Tampa, Florida 33634, US |
Phone | (813) 286-7900 |
Fax | (813) 286-7904 |
Technologies |
JavaScript,
HTML,
Google Analytics
+13 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Probiotcs, Healthcare, Science and Engineering, Pharmaceutical, Health Care, Therapeutics |
Web Rank | 2 Million |
Keywords | Oragenics, Ogen Stock Public Offering, Oragenics Inc, Ogen, Organeics |
Competitors | BioVersys AG, Cempra Pharmaceuticals, ProBiora Health LLC, Sequella, Inc., TAXIS Pharmaceuticals Inc |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Oragenics, Inc employee's phone or email?
The Oragenics, Inc annual revenue was $87000 in 2024.
Charles Pope is the Chairman of the Board and Chairman Audit Committee of Oragenics, Inc.
13 people are employed at Oragenics, Inc.
Oragenics, Inc is based in Tampa, Florida.
The NAICS codes for Oragenics, Inc are [32541, 3254, 325, 32].
The SIC codes for Oragenics, Inc are [28, 283].